Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ: BIIB )

157.90 -0.11 (-0.07%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 22, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
48 49 Next >
7 Undervalued S&P 500 Stocks to Buy in June
If you want to maximize your upside potential in a relatively predictable arena, these undervalued S&P 500 stocks could be for you. 
Via InvestorPlace
Senator Bernie Sanders Puts Brakes on Health Agency Nominees Until Drug Pricing Issue is Addressed
Senator Bernie Sanders vowed to oppose President Joe Biden's nominated candidate, Monica Bertagnolli, or any other current or future health agency nominee, to lead the National Institutes of Health... 
Via Benzinga
Why Biogen Stock Is Trading Down Today
Biogen Inc. (NASDAQ: BIIB) shares fell Tuesday after it was deemed that the ability of the company's Alzheimer's drug, Leqembi, to slow cognitive decline may not outweigh its risks, according to... 
Via Benzinga
Methode Electronics, Brookfield Renewable Partners And Other Big Stocks Moving Lower On Tuesday
U.S. stocks traded higher, with the Dow Jones rising around 100 points on Tuesday. Here are some big stocks recording losses in today’s session. 
Via Benzinga
FTC Sues To Block Microsoft-Activision Blizzard Deal, Netflix's First Sports Streaming Debut, EU Mulls Antitrust Case Against Google's Ad-Tech Business: Today's Top Stories
Benzinga 
Via Benzinga
Expert Ratings for Biogen
Via Benzinga
Alzheimer's Drug Leqembi Faces Hurdles in Europe: Concerns Over Health Risks and Healthcare Resources
Experts in Europe considering the potential use of a new Alzheimer's disease drug developed by Eisai Co Ltd (OTC: ESALY) and Biogen Inc (NASDAQ: BIIB) say Leqembi (lecanemab)'s ability to slow 
Via Benzinga
Biogen Announces Changes to Its Board of Directors
From Biogen Inc.
Via GlobeNewswire
Macro Muddle Coming Up As Market Exceeds Expectations, Small Caps Gain Ground
For the bull run to continue we need broader market participation from SMID caps. 
Via Talk Markets
Prospects for Full Approval of Eisai and Biogen's Leqembi Shine Brighter after FDA Committee Vote
Friday, the FDA's Peripheral and Central Nervous System Drugs Advisory Committee voted unanimously that the data from Eisai Co Ltd (OTC: ESALY) and Biogen Inc (NASDAQ: BIIB) Phase 3 Clarity AD tria 
Via Benzinga
$100 Invested In Biogen 15 Years Ago Would Be Worth This Much Today
Via Benzinga
Biogen Unusual Options Activity For May 26
Via Benzinga
Analyst Ratings for Biogen
Via Benzinga
If You Invested $1000 In This Stock 15 Years Ago, You Would Have $5,500 Today
Via Benzinga
Why Are Cruise Stocks CCL, RCL, NCLH Up Today?
Cruise stocks are on the rise Monday as investors react to a positive note to clients from JPMorgan analysts and we've got the details! 
Via InvestorPlace
BIIB Stock Alert: Biogen Resumes Trading With New FDA Backing
Biogen (BIIB) stock is a hot topic among traders Monday as the company's share resumed trading following a halt that was in effect on Friday. 
Via InvestorPlace
Nasdaq, S&amp;P 500 Futures Signal Strong Start To Week On Hopes Of Fed Pause: Why This Analyst Is Pricing In A 20% Gain From Bear Market Low
Via Benzinga
FDA Advisory Committee Votes Unanimously to Confirm the Clinical Benefit of LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer’s Disease
From Biogen Inc.
Via GlobeNewswire
Biogen Stock Halted As It Faces Make-Or-Break Moment For Alzheimer's Treatment
A panel of experts will debate the merits of Biogen's drug, Leqembi. 
Via Investor's Business Daily
Bernie Sanders Takes on High Costs of Alzheimer's Treatment Leqembi, Calls Price Tag 'Unconscionable'
Senator Bernie Sanders urged the U.S. 
Via Benzinga
FDA Signals Support for Eisai-Biogen Alzheimer's Drug Data Confirms Benefits For Complete Approval
FDA Peripheral and Central Drugs Advisory Committee is meeting Friday (June 9) to discuss a supplemental marketing application for Leqembi (lecanemab) submitted by Eisai Co Ltd (OTC: ESALY) for... 
Via Benzinga
Biogen Rises As 'Relatively Benign' FDA Documents Suggest An Alzheimer's Approval Is Near
The FDA's advisors will consider the full approval of Leqembi on Friday. 
Via Investor's Business Daily
Thinking Of Buying Boston Properties? Here Are The Properties And Tenants You'd Add To Your Portfolio
When investors consider the purchase of a real estate investment trust (REIT), along with performance and dividends, they need to consider the properties and tenants that accompany that REIT. Several... 
Via Benzinga
Biogen and Denali Realign Parkinson's Disease Research Priorities Amidst R&D Restructure
Via Benzinga
The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree
Big Pharma is facing a patent cliff that could siphon off billions in revenue. 
Via Investor's Business Daily
Biogen Hits Buy Zone On A Fresh Win In Alzheimer's Disease; Eli Lilly, Eisai Shares Jump
The news also benefits Biogen's partner Eisai and rival Eli Lilly. 
Via Investor's Business Daily
How Biohaven Is Coming 'Out Of Stealth Mode' — And Bullishly Extending A 4-Day Run
Shares surged into and out of the company's R&D Day, which included a surprise. 
Via Investor's Business Daily
Rotation Out Of Healthcare And Biotech Stocks: Age Of Disruption?
A steady rotation out of biotech and healthcare stocks into the Nasdaq-100 large-cap tech stocks can be unnerving for portfolio managers. 
Via Talk Markets
3 Biotech Stocks That Are Revolutionizing Healthcare in 2023
Here are three of the best biotech stocks to buy; each is on the verge of significant breakthroughs that may send the price higher. 
Via InvestorPlace
1 Major Advantage Biogen May Have Over Pharma Giant Eli Lilly in a Multibillion-Dollar Market
Analysts are bullish on Biogen's Alzheimer's drug, Leqembi, projecting it may generate over $10 billion in sales at its peak. 
Via The Motley Fool
< Previous 1 2
...
12 13 14 15 16 17 18 19 20
...
48 49 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.